Cytokinetics, Inc.

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/24/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the opening to enrollment of the second cohort in the ongoing, international, randomized, double-blind, placebo-controlled Phase IIb clinical trial of an intravenous formulation of omecamtiv mecarbil, known as ATOMIC-AHF (Acute Treatment with Omecamtiv ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 05/15/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that its Annual Meeting of Stockholders will be held on Tuesday, May 22, 2012 at 10:00 AM Pacific Time at the Embassy Suites Hotel, located at 250 Gateway Boulevard in South San Francisco, ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/26/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that preclinical data regarding CK-2017357 were presented in a poster presentation at the 2012 Experimental Biology Annual Conference in San Diego, California. CK-2017357 is the lead drug candidate from the company's skeletal muscle contractility ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/25/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today encouraging results from two Phase II clinical trials evaluating CK-2017357 in patients with amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease. In these studies, CK-2017357 was determined to be safe and ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/19/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report first quarter results on Thursday, April 26, 2012 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call at 4:30 PM ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/19/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that CK-2017357, its fast skeletal muscle troponin activator, has received Fast Track designation from the U.S. Food and Drug Administration (FDA) for the potential treatment of amyotrophic lateral sclerosis (ALS), also commonly known ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 04/18/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that one oral presentation and two poster presentations are scheduled to be presented at the 64th Annual Meeting of the American Academy of Neurology, to be held April 21-28, 2012 in New Orleans, ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/27/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the Eleventh Annual Needham Life Sciences Conference on Tuesday, April 3, 2012 at 2:00 PM Eastern Daylight Time at ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/07/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the resignation of James A. Spudich, Ph.D. from the company's Board of Directors. Dr. Spudich co-founded the company and has served on the company's Board since its inception. Contemporaneously with Dr. Spudich's resignation, ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/06/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the European Medicines Agency (EMA) has granted the company's fast skeletal muscle troponin activator CK-2017357 orphan medicinal product designation for the treatment of amyotrophic lateral sclerosis (ALS), also commonly known as Lou ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 03/05/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the publication of preclinical research regarding the activation of the troponin complex of fast skeletal muscle by its drug candidate CK-2017357 and the potential therapeutic role that this novel mechanism may play for ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/28/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present at the following healthcare conferences during the month of March: Cowen & Company 32nd Annual Health Care Conference Date: Tuesday, ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/21/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today the initiation of a Phase I study designed to assess the safety, tolerability and pharmacokinetics of multiple oral formulations of omecamtiv mecarbil in healthy volunteers. This clinical trial is being conducted by Amgen ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/06/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that Robert I. Blum, President and Chief Executive Officer, is scheduled to present a corporate update at the BIO CEO and Investor Conference on Monday, February 13, 2012 at 1:00 p.m. Eastern Standard ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 02/02/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) reported total research and development revenues of $0.8 million for the fourth quarter of 2011. The net loss for the fourth quarter was $11.9 million, or $0.16 per basic and diluted share. This compared to ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 01/26/12 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it is scheduled to report fourth quarter and year end results on Thursday, February 2, 2012 at 4:00 PM Eastern Time. Following the announcement, Cytokinetics' senior management will host a conference call ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/30/11 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today positive results from the first cohort, or Part A, of a continuing Phase II clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS). Data were presented at the 22nd International Symposium ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/29/11 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that the company has opened enrollment in a third Phase II clinical trial of CK-2017357 in patients with amyotrophic lateral sclerosis (ALS). CK-2017357 selectively activates the fast skeletal muscle troponin complex by increasing ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/25/11 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that it has filed a shelf registration statement on Form S-3 with the U.S. Securities and Exchange Commission (SEC). The shelf registration statement, if declared effective by the SEC, will allow the Company ... read more

SOUTH SAN FRANCISCO, CA -- (Marketwire) -- 11/22/11 -- Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that two posters are scheduled to be presented at the 22nd International Symposium on ALS/MND to be held November 30, 2011 - December 2, 2011 at the Hilton Sydney in Sydney, Australia. One poster will ... read more